Tapan M. Kadia, MD. Professor, Department of Leukemia, Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX
Tapan Kadia, MD, a professor at MD Anderson Cancer Center, discusses acute myeloid leukemia (AML) maintenance therapy at the MD Education Conference. He highlights azacitidine as a standard treatment. After exploring various post-consolidation strategies, hypomethylating agents have emerged, extending remissions after stem cell transplantation.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
He details fluid inhibitors for post-transplant and maintenance in specific mutations. Novel combinations, like pairing oral hypomethylating agents with targeted and immune therapies, aim to extend remission and cure more AML patients. Kadeem praises the conference’s great speakers, engaged audience, and interactive discussions, fostering valuable connections.